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Von Willebrand Disease: the viability of a 
technology-based diagnosistic modality
Ted Gutches
Longwood University Department of Biological and 
Environmental Sciences
Introduction
VWF Structure & Function
Specific Aims
• Von Willebrand disease (VWD) is an autosomal inherited 
bleeding disorder.
• The VWF is a multimeric plasma glycoprotein that binds to 
platelets in order to deliver factor VIII, another essential 
blood clotting protein, to sites in which vascular injury has 
occurred.[2,4]
• Three types include: Type 1 (partial deficiency), Type 2 
(qualitative deficiency), and Type 3 (complete deficiency).
• Type 1, the mild case, makes up 65% to 80% of cases; type 
2, the moderate and qualitatively abnormal case of VWD, 
makes up 20% to 35% of cases; with type 3, the severe 
case, affecting 1 in 1 million people.[5]
• Variations in Type 2 include: defects in multimerization 
(type 2A), spontaneous platelet binding (type 2B), defects 
in ligand binding with multimers (type 2M) and defects in 
factor VIII binding (type 2N). 
• Next-Generation Sequencing has shown promise in its 
diagnostic application but has not yet been implemented 
for small-scale patient diagnostics.[1]
Figure 1: The visualization of von Willebrand factor in the formation of a clot for the coagulation 
cascade.[4]
Methodology
• By first identifying the challenges clinicians face when 
determining the proper diagnosis of a VWD patient, this 
study aims to seek an improvement in diagnostic techniques, 
by implementing the clinical use of genetic testing.
• More specifically, this study aims to improve the total 
diagnostic time for the intermediate forms of VWD, through 
the clinical application of Next-Generation Sequencing.
Patient Population and Blood Sampling
• Willing patients who have previously been diagnosed 
with VWD
• ~4mL of blood will be used from each patient
Amplification and Sequencing
• Oligonucleotides will be used for amplification of 
exons
• Multiplex PCRs will be used for amplification of the 
VWF
• Each amplicon will be processed and analyzed
• A MiSeq platform will be used for sequence analysis[1]
Sequence Analysis
• NGS will be used for identification of specific variants, 
further confirmed via Sanger sequencing
• Categorization of the disease according to type will be 
recorded
Potential Conclusions
• NGS could provide viable results that could advocate for a 
transition towards a clinically applied system of genetic 
screening for patients with intermediate forms of VWD
• Identifying new variants among the three types of VWD, 
through the continued use of gene sequencing for the VWF, 
could broaden the diagnostic spectrum of VWD, to which 
clinicians refer.
Potential Pitfalls
• Providing necessary tools in order to reduce costs of small-
scale genetic testing for patients in a clinical setting could 
present limitations in the effort for implementation for this 
diagnostic modality
• Further specification for warranting such a diagnostic tool 
would require additional evaluations
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Figure 2: von Willebrand Factor is a multimeric oligomer that exists in multiple domains. Domain A2 is 
shown and is said to be unprotected from unfolding via disulfide bonds.[3]
